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Metaflammation, an atypical, metabolically induced, chronic low-
grade inflammation, plays an important role in the development of
obesity, diabetes, and atherosclerosis. An important primer for
metaflammation is the persistent metabolic overloading of the
endoplasmic reticulum (ER), leading to its functional impairment.
Activation of the unfolded protein response (UPR), a homeostatic
regulatory network that responds to ER stress, is a hallmark of all
stages of atherosclerotic plaque formation. The most conserved ER-
resident UPR regulator, the kinase/endoribonuclease inositol-requir-
ing enzyme 1 (IRE1), is activated in lipid-laden macrophages that
infiltrate the atherosclerotic lesions. Using RNA sequencing in macro-
phages, we discovered that IRE1 regulates the expression of many
proatherogenic genes, including several important cytokines and
chemokines. We show that IRE1 inhibitors uncouple lipid-induced ER
stress from inflammasome activation in both mouse and human
macrophages. In vivo, these IRE1 inhibitors led to a significant decrease
in hyperlipidemia-induced IL-1β and IL-18 production, lowered T-helper
type-1 immune responses, and reduced atherosclerotic plaque size
without altering the plasma lipid profiles in apolipoprotein E-deficient
mice. These results show that pharmacologic modulation of IRE1 coun-
teracts metaflammation and alleviates atherosclerosis.
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Complex molecular interactions between environment, diet,and genetics that take place at the metabolic and immune
interface provoke a low-grade, chronic inflammatory response—
metaflammation—that engages cells of the immune system (mac-
rophages, neutrophils, and lymphocytes) and metabolic tissues
(adipocytes, hepatocytes, and pancreatic cells) (1). An important
primer for metaflammation is chronic metabolic overloading of
organelles, such as the endoplasmic reticulum (ER) and mito-
chondria, which results in impairment of their functions (2).
The ER serves essential cellular functions that include the
synthesis and folding of secreted and transmembrane proteins,
calcium storage, and lipid synthesis for membrane biogenesis or
energy storage. Disruption of any of these functions leads to ER
stress and the subsequent activation of an elaborate network of
adaptive responses, collectively known as the unfolded protein
response (UPR) (3). The UPR reestablishes homeostasis through
both transcriptional and translational layers of control. The UPR
signals through three mechanistically distinct branches that are
initiated by the ER-resident protein folding sensors inositol-
requiring enzyme 1 (IRE1), protein kinase RNA-like endoplasmic
reticulum kinase (PERK), and activating transcription factor 6
(ATF6) (3).
IRE1 controls the phylogenetically most conserved branch of
the UPR found from fungi to metazoans. It has an ER-lumenal
sensor domain that recognizes unfolded peptides and cytosolic
kinase and endoribonuclease (RNase) domains that relay the in-
formation to downstream effectors (3). On sensing unfolded
proteins, IRE1 oligomerizes and trans-autophosphorylates, thereby
activating its RNase function. Metazoan IRE1 possesses two
functional outputs dependent on its RNase activity. (i) It initiates a
nonconventional splicing reaction that processes the mRNA
encoding X-box binding protein-1 (Xbp1) to allow the translation
of its active form, XBP1s, a potent transcription factor that, to-
gether with ATF6, drives expression of numerous genes, including
those encoding ER-resident chaperones and ER-associated protein
degradation machinery (3). (ii) IRE1 selectively degrades ER-
bound mRNAs in a process known as regulated inositol-requiring
enzyme 1-dependent decay (RIDD) to alleviate ER load (4). By
these mechanisms, UPR activation reinstates homeostasis.
Increased ER stress and activation of the UPR are well-docu-
mented in atherosclerosis (5). Many metabolic cardiovascular risk
factors observed in obesity, including hyperglycemia, hypercholes-
terolemia, and elevated saturated fats, can induce ER stress in all
stages of atherogenesis, the process leading to the development of
atherosclerotic plaques. During atherogenesis, a maladaptive in-
flammatory response is initiated by the deposition of cholesterol-rich
lipoproteins in the subendothelial layer of arterial walls (6). Signs of
ER stress are most prominent in the atherosclerosis-prone regions of
vascular lesions, such as the branching points of arteries, and typically
observed in macrophages—among other immune cells—infiltrating
these regions (7, 8). Chronic, irremediable ER stress triggers apo-
ptosis in macrophages, contributing to the growth of the necrotic core
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that is observed in atherosclerotic plaques, which leads to a sub-
sequent reduction in plaque stability, promoting their rupture (5).
Work over the last decade has pinpointed ER stress as a
driving force for atherosclerosis progression (5, 7–10). For
example, inhibiting the apoptotic signaling downstream of ER
stress through genetic deletion of the proapoptotic tran-
scription factor CCAAT box binding enhancer homologous
protein (CHOP) or the signal transducer c-jun N-terminal
kinase (JNK) blocks atherosclerosis progression (5, 11–13).
Moreover, modulation of ER stress by using chemical chap-
erones alleviates atherosclerosis, further supporting the idea
that therapeutic modulation of ER function is a promising
avenue to combat atherosclerosis (14–16). Precedence for this
notion is provided by pharmacological approaches to improve ER
function—and thereby, limit ER stress—that include autophagy
inducers, antioxidants, and regulators of ER calcium homeo-
stasis (17–19).
Recent drug discovery efforts have opened the door to ap-
proaches that entail selective modulation of UPR signaling. This
quest has led to the identification of several new small molecules
that target the enzymatic activities of specific UPR regulators
(19–23). Specifically, blocking IRE1 or XBP1s function has been
shown to be beneficial for restraining tumor progression in
mouse models (21, 24), highlighting that the specific targeting of
the UPR can have beneficial impact in disease.
Several lines of evidence support the notion that selective
pharmacological targeting of IRE1 is a desirable therapeutic ap-
proach for treatment of atherosclerosis. First, a profound increase
in IRE1 phosphorylation and XBP1s expression is observed in
atherosclerotic plaques of mice and humans (8, 10). Second,
mechanical sheer stresses activate IRE1, whereas cardiovascular
disease risk factors, such as oxidized phospholipids and homo-
cysteine, induce both IRE1 and PERK (5, 25–29). Third, experi-
mentally sustained Xbp1 mRNA splicing in the vessel wall
promotes atherosclerosis, whereas its ablation ameliorates hyper-
cholesterolemia in obese or apolipoprotein E-deficient (ApoE−/−)
mice (10, 30). Two small molecules, STF-083010 and 4μ8C, which
selectively inhibit IRE1’s RNase function, have been used in cells
and animals to produce favorable therapeutic outcomes in other
disease settings: STF-083010 reduced growth of multiple myeloma
(21, 24, 31, 32), and 4μ8c suppressed inflammation in a murine
arthritis model (33). The action of both compounds is well-
understood mechanistically. Both form a Schiff base with a specific
lysine positioned in the active site of the IRE1 RNase domain,
blocking its function, and both show no overt toxicity when ad-
ministered systemically (21, 32, 33). Thus, we reasoned that these
drugs might have therapeutic applicability in atherosclerosis.
Here, we investigated the direct contribution of IRE1 to lipid-
induced inflammation and atherosclerotic disease progression by
administering these two IRE1 inhibitors to macrophages and
ApoE−/− mice on a Western-type (high-fat and high-cholesterol)
diet. Our results substantiate the concept that specific pharma-
cological modulation of IRE1 counteracts metaflammation and
yields therapeutic gains in atherosclerotic disease, warranting
additional validation in human disease.
Results
Proatherogenic Genes Are Regulated by IRE1. To understand the
contributions of IRE1 in atherogenesis, we first analyzed the
impact of its inhibition on the transcriptome of macrophages using
RNA sequencing (RNA-seq). ER poisons, such as tunicamycin,
which inhibits protein N-linked glycosylation in the ER lumen, or
thapsigargin, which disrupts ER calcium reuptake, activate all
UPR branches simultaneously, impeding the dissection of the
signaling contributions of individual UPR branches. By refraining
from using these pleiotropic drugs, we aimed to identify the spe-
cific IRE1-regulated gene expression changes. To this end, we
probed the transcriptional response to acute inhibition of IRE1
using STF-083010 in primary mouse bone marrow-derived mac-
rophages (BMDMs) (34, 35). We analyzed differentially regulated
mRNAs at early time points (6 hours) after IRE1 inhibition to
distinguish immediately responsive genes from those with ex-
pression that may be altered as part of an adaptive response to
chronic inhibition. Using an arbitrary cutoff of 1.5-fold, we ob-
served increased expression of 169 genes and decreased expres-
sion of 135 genes on IRE1 inhibition (Fig. 1A, Dataset S1, and
Tables S1 and S2) (P < 0.05). To categorize the affected genes
functionally according to their association with disease processes,
we used the Ingenuity Pathway Analysis (IPA) tool (36). IPA
identified the down-regulation of many important proatherogenic
genes, including cytokines, chemokines, and chemokine receptors,
on inhibition of the steady-state IRE1 activity (Fig. 1B).
We next validated our findings using quantitative (q)RT-PCR.
In these experiments, we observed a significant reduction in the
mRNA levels of Il-1β, C-C motif chemokine ligand 2 (Ccl2),
calgranulin A (S100a8), and matrix metalloprotease-9 (Mmp9)
(P < 0.05, P < 0.001, P < 0.01, and P < 0.01, respectively) after
IRE1 inhibition with either STF-083010 or 4μ8c (Fig. 1 C–E and
Fig. S1 A–E). Both of these drugs were used at concentrations
that do not compromise cell viability or induce any other toxicity
(21, 34, 35, 37–40). Consistent with earlier reports, these IRE1
inhibitors had no effect on the kinase function of IRE1 (Fig. S1
F–H), confirming that the identified proatherogetic genes are
regulated by IRE1’s RNase activity.
Because IRE1 is rate-limiting for the production of XBP1s, we
next assessed if XBP1s regulates the expression of these proa-
therogenic genes. To this end, we forced expressed XBP1s or
restored IRE1 function in inositol-requiring enzyme 1-deficient
(IRE1−/−) mouse embryonic fibroblasts (MEFs) (Fig. S1I). Both
experiments showed a marked induction of Il-1β, Ccl2, and S100a8
mRNA levels (Fig. 1 F–H). Together, our findings confirm that
the IRE1-XBP1 signaling branch of the UPR maintains the
expression of key proatherogenic cytokines and chemokines
in macrophages.
Induction of IL-1β and CCL2 Depends on IRE1 During Lipotoxicity.Our
finding that IRE1 maintains the expression of several important
proatherogenic genes in macrophages suggests that, when in-
duced by metabolic stress, heightened IRE1 activity could drive
the atherosclerotic process. One important activating signal for
the UPR in macrophages is exposure to excessive amounts of
lipids, which elicits toxicity (14, 28, 41). This lipotoxicity results in
increased production of reactive oxygen species (ROS), ER
stress, and inflammation, and it can result in apoptosis (41).
Based on these observations, we next investigated if lipid-
induced IRE1 activation plays a role in IL-1β induction. Inhibition
of IRE1 with STF-083010 led to a significant block in lipid-
induced Il-1β mRNA production and secretion from BMDMs
(Fig. 2 A and B and Fig. S2 A and B). As expected, inhibition of
IRE1 activity with 4μ8c showed the same effects (Fig. S2 C–F). To
further delineate the role of IRE1 and XBP1s in the regulation of
IL-1β, we transfected BMDMs with a specific siRNA. We found
that transfection of siRNAs against Ire1α (the ubiquitously
expressed IRE1 homolog) or Xbp1 resulted in a significant re-
duction in lipid-induced Il-1β mRNA production and IL-1β se-
cretion in BMDMs [Fig. 2 C and D (P < 0.05, P < 0.05, P < 0.001,
and P < 0.001) and Fig. S2 G and H]. Moreover, treatment of
human peripheral blood monocytes (PBMCs) with lipids induced
IL-1β secretion, which was blocked by preincubation with 4μ8c
(Fig. 2 E and F and Fig. S2I). These findings show that IRE1-
XBP1 signaling plays an important role in Il-1β mRNA up-regu-
lation and secretion from both mouse and human macrophages.
We also investigated if the proatherogenic chemokine CCL2 is
regulated by IRE1 under lipotoxic ER stress conditions. Both
STF-083010 and 4μ8c treatments of BMDMs resulted in com-
plete inhibition of lipid-induced Ccl2 mRNA production and
protein secretion (Fig. S3 A–C). Consistent with this observation,
siRNAs against Ire1α or Xbp1 also suppressed lipid-induced
CCL2 production and secretion in BMDMs (Fig. S3 D and E).
Moreover, 4μ8c blocked lipid-induced CCL2 production in hu-
man PBMCs (Fig. S3F). Collectively, these data show that IRE1
is important for the inflammatory response to lipids and the
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production of proatherogenic cytokines in both mouse and
human macrophages.
Inflammasome Activation Depends on IRE1 During Lipotoxicity. Be-
cause IRE1 inhibition leads to a strong suppression of IL-1β
secretion, we reasoned that IRE1 may contribute to the lipid-
induced activation of the Nod-like receptor family, pyrin
domain-containing protein-3 (NLRP3) inflammasome, a multi-
component platform that contains caspase-1 and induces the
caspase-1–dependent secretion of the proinflammatory cytokines
IL-1β and IL-18 (42, 43). Previous studies showed that ER stress
induces inflammasome activation through several mechanisms,
including calcium mobilization and the release of reactive ox-
ygen species from damaged mitochondria (mtROS) (44). Be-
cause earlier studies from our laboratory and the laboratories
of others showed that treatment of macrophages with saturated
fatty acids activates IRE1 and because these lipids specifically
activated the NLRP3 inflammasome through inducing mtROS
production, we sought to investigate this connection further
(42, 43, 45). To this end, we first measured mtROS production
in cells exposed to lipotoxic stress in the presence of IRE1 in-
hibitors. We observed that lipid-induced ER stress in BMDMs
resulted in a dramatic elevation of mtROS, which was com-
pletely blocked by 4μ8c treatment as well as XBP1 knockdown
(Fig. 3 A and B and Fig. S4A).
The impact of IRE1 signaling on inflammasome activation has
been postulated to be mediated by the IRE1-dependent accu-
mulation of the thioredoxin-interacting protein (TXNIP), a thi-
oredoxin inhibitor with increased levels that promote activation
of the NLRP3 inflammasome (35). In stark contrast to these
earlier findings, which used cells treated with canonical ER
poisons, lipid-induced ER stress led to a profound suppression of
BA
























S100A8 s100 Calcium Binding Protein A8 -3,83 5,00E-05
CCR2 Chemokine (C-C) Motif Receptor 2 -2,98 5,00E-05
CCL2 The chemokine (C-C motif) ligand 2 -2,73 6,00E-03
IL-1β Interleukin 1, Beta -2,58 4,09E-02
CCR3 Chemokine (C-C) Motif Receptor 3 -2,48 1,30E-02
PLA2R1 Phospholipase A2 Receptor 1 -2,04 2,72E-02
ITGA4 Integrin, Alpha 4 -1,93 5,00E-05





    
    











































    
    


































































































    
    









Fig. 1. IRE1 regulates the expression of proatherogenic genes. (A) RNA-seq analysis in BMDMs treated with 60 μM STF-083010 or DMSO (control) for 6 hours.
Volcano plot of differentially expressed mRNAs. (B) Analysis of atherosclerosis-related mRNAs using the IPA tool (details are in the text). (C–E) Confirmation of
IRE1-dependent atherogenic gene regulation in mouse BMDMs treated with STF-083010 or DMSO (control) by qRT-PCR. (F–H) qRT-PCR analysis of atherogenic
gene expression in IRE1−/− MEFs on forced expression of XBP1s or restoring IRE1’s function. Data: mean values ± SEM; n = 3. Student’s t test. Ctrl, control; ns,
not significant. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.














TXNIP in macrophages, which was partially blocked by inhibit-
ing IRE1 (Fig. S4B). Another mechanism by which ER stress can
induce mitochondrial oxidative stress and activation of the
NLRP3 inflammasome complex is through calcium mobilization
(46). Indeed, we observed that palmitic acid (PA) leads to a
significant increase (threefold) of calcium levels in the mito-
chondria, but this increase could not be prevented by IRE1 in-
hibition (Fig. S4C). Moreover, lipid-induced ER stress also
induced procaspase-1 maturation (indicated by the appearance
of the p10 fragment), an effect that was reduced by treatment
with IRE1 inhibitors or siRNA-mediated silencing of Ire1α and
Xbp1 (Fig. 3C and Fig. S4 D and E). Taken together, these re-
sults indicate that IRE1 plays a crucial role in perpetuating
mtROS production and NLRP3 inflammasome activation in
cells experiencing lipotoxic ER stress but that this effect is in-
dependent of TXNIP induction and calcium mobilization.
We further investigated if IRE1 affects the activation of the
NLRP3 inflammasome by other stimuli or the activation of dif-
ferent inflammasome complexes by specific inducers. Although
IRE1 inhibition blocked NLRP3 inflammasome activation, cleav-
age of caspase-1, and secretion of IL-1β by various different
NLRP3 inflammasome inducers (including ATP, Alum, and cho-
lesterol crystals) (Fig. 3D), it did not alter the activation of other
inflammasome complexes, such as NLR family CARD domain-
containing protein 4 by flagellin or absent in melanoma 2 by
poly(deoxyadenylic-deoxythymidylic acid) [poly(dA:dT)] as evident
by no changes in caspase-1 cleavage (Fig. 3E). Because IRE1-XBP1
controls Il-1β mRNA production, we observed reduction in secreted
IL-1β protein levels in all of the treatments (Fig. 3D and E). Finally,
together with our results showing that IRE1 induces IL-1β, our data
show that IRE1 plays a major role in controlling IL-1β signaling
both transcriptionally and by promotion of its maturation via the
activation of the NLRP3 inflammasome.
Pharmacological Inhibition of IRE1 Combats Atherosclerosis. The
evidence presented above in conjunction with previous results
showing that restoring or improving ER function alleviates ath-
erosclerosis (14, 17, 47) suggest that inhibiting IRE1 may impair
atherosclerosis progression. Therefore, we postulated that ad-
ministration of IRE1 modulators might have beneficial effects by
limiting the inflammatory signaling associated with elevated ER
stress in a mouse model of atherosclerosis. To test this notion, we
challenged ApoE−/− mice with a Western diet (12 weeks) and then
treated them daily with STF-083010 by intraperitoneal (i.p.) in-
jection (6 weeks) (Fig. 4A). Although limited pharmacodynamic
data are available for the IRE1 inhibitors that we used, target
engagement has been shown in cells and tissues (21, 39). We based
our in vivo drug dosage and delivery on earlier in vivo studies that
successfully administered the IRE1 modulators without toxicity
(21, 24, 31). Furthermore, we confirmed target engagement in
tissues by assessing drug-induced suppression of Xbp1 mRNA
splicing and RIDD activities by observing a significant reduction in
the spliced Xbp1 mRNA (P < 0.05) and a modest increase in
canonical RIDD target mRNAs (P < 0.05) (Fig. S5 A–C). Im-
portantly, the IRE inhibitor that we used did not alter IRE1
phosphorylation in vivo (Fig. S5D). Furthermore, we detected no
differences in body weights, blood glucose levels, liver morphol-
ogy, plasma alanine amino transferase (ALT) activity, and cho-
lesterol profiles between the STF-083010–treated and control
groups (Figs. S5 E and F and S6 and Table S3). However, the
analysis of en face aorta preparations showed that chronic ad-
ministration of STF-083010 led to a significant decrease (35.8%;
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Fig. 2. IRE1 regulates lipid-induced IL-1β secretion in mouse and human macrophages. Il-1β (A) mRNA and (B) protein levels measured from LPS-primed and
PA-stimulated mouse BMDMs treated with 150 μM STF-083010 or DMSO (control) by qRT-PCR and ELISA, respectively. Il-1β (C) mRNA and (D) protein levels
measured from LPS-primed and PA-stimulated mouse BMDMs transfected with siRNAs against Ire1α or Xbp1 by qRT-PCR and ELISA, respectively. (E) Secreted
IL-1β from LPS-primed, PA-stimulated human PBMCs treated or not treated with 100 μM 4μ8c measured by ELISA. (F) Same as E but protein levels were
measured by immunoblotting to show the immature and processed forms of the cytokine (representative image of three independent blots). Statistics are the
same as in Fig. 1. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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group (Fig. 4B). Furthermore, when we evaluated the impact of
STF-0803010 on plaque development in the aortic root, we ob-
served a significant reduction (21.4%; P < 0.001) in the foam cell
area (visualized by Oil Red O staining) in the inhibitor-treated
group compared with control mice (Fig. 4C).
Analogous experiments using 4μ8c in the same animal model
[using previously published doses that showed no toxicity (33, 37,
40, 48)] produced similar results (Fig. 4D–F): 4μ8c treatment led to
a significant reduction (45.2%; P < 0.001) in atherosclerotic lesion
area in en face aorta preparations (Fig. 4E) and a significant re-
duction in the spliced Xbp1 mRNA (Fig. S7A) (P < 0.05) but no
change in IRE1 phosphorylation in the spleens (Fig. S7B). Fur-
thermore, 4μ8c treatment led to a reduced foam cell area (Fig. 4F)
without overt differences in body weight, blood glucose levels
(Table S4), liver morphology, and plasma ALT activity between the
inhibitor-treated and control mice (Fig. S7 C and D). These in vivo
findings show that pharmacological inhibition of IRE1 can effec-
tively mitigate plaque development in mice.
Pharmacological Inhibition of IRE1 Alters Plaque Composition. En-
dothelial cells, vascular smooth muscle cells (VSMCs), and im-
mune cells, such as lymphocytes, dendritic cells, neutrophils, and
macrophages, play important roles in the development of ath-
erosclerotic plaques in the arterial wall. The UPR is activated in
many of these cell types and at all stages of atherosclerotic plaque
development. This increase in ER stress is also associated with
plaque progression, vulnerability to rupture, and acute coronary
syndrome in humans (7). Given that IRE1 inhibitors alleviated
atherosclerosis in ApoE−/− mice, we next analyzed the impact of
these inhibitors on the cellular composition of the lesions. STF-
083010 treatment led to a significant reduction (35%; P < 0.01) in
macrophages [as visualized by monocyte/macrophage marker-2
(MOMA-2) staining] infiltrating the aortic root plaques (Fig. 5A).
This reduction in macrophage numbers was not the product of
increased apoptosis as determined by TUNEL (in situ cell death
detection) assays in macrophage-enriched areas of the plaques
(Fig. 5B). Furthermore, there were no differences in the necrotic
core area between the treatment and control groups (Fig. S8A).
During plaque formation, VSMCs migrate from adventitia to in-
tima, secreting collagen and sealing the fibrous cap of the plaque.
The analysis of the lesions in STF-083010–treated mice (with
Masson’s Trichrome staining) showed that there is a significant
increase in collagen content that is responsible for tensile strength
and elasticity of the plaques (22%; P < 0.05) without changes in
the numbers of the VSMCs infiltrating the lesions (Fig. S8 B and
D). However, we did not observe significant differences in the
fibrous cap thickness between the treatment and control groups
(Fig. S8C) Finally, STF-083010 treatment did not alter CD3+
T-cell numbers in the adventia/lesions (Fig. S8E). Taken together,
these results indicate that the major consequences of IRE1
inhibition include a reduction in macrophages and an increase
in collagen deposition in atherosclerotic plaques.
Last, we sought in vivo evidence for the observed inhibition of
IL-1β by IRE1 inhibition in macrophages (Figs. 1 and 2). We
observed that STF-083010 treatment reduced the expression of
IL-1β in the aortic root lesions stained with a specific antibody
against IL-1β (Fig. 5C). Together, these results validate our earlier
in vitro findings and show that the antiatherogenic effect of IRE1
inhibitors involves a blockage of inflammation in the lesions.
IRE1 Inhibitors Suppress Hyperlipidemia-Induced Th-1 Immune
Responses. Atherosclerosis initiation and progression depend on
both innate and adaptive immunity pathways. T cells orchestrate
adaptive immunity, whereas macrophages bridge innate and
adaptive immune processes that contribute to lesion development.
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Fig. 3. IRE1 inhibitors block lipid-induced mtROS release and inflammasome activation. (A and B) mtROS production was measured in LPS-primed, PA-
stimulated mouse BMDMs after (A) 100 μM 4μ8c or DMSO (control) treatment or (B) transfection with scrambled or Xbp1-specific siRNAs. (C–E) Immunoblots
of the levels of the zymogen (p45) and mature (p10) forms of caspase-1 in LPS-primed mouse BMDMs pretreated with 4μ8c (at the indicated doses) or DMSO
(control) and stimulated with (C) PA, (D) other NLRP3 agonists (5 nM ATP, 200 μg/mL alum, or 400 μg/mL cholesterol crystals), or (E) specific activators of other
inflammasome complexes [5 μg/mL poly(dA:dT) and 1 μg/mL flagellin] according to previously published protocols (described in detail in Experimental
Procedures). Blots shown are representative of three independent experiments. Statistics are the same as in Fig. 1. CE, cell extract; SN, supernatant. *P ≤ 0.05;
**P ≤ 0.01; ***P ≤ 0.001.














plaques. Th-1 cells are proinflammatory, produce high amounts of
IFN-γ, and contribute to the progression of atherosclerosis. Two
other types of lymphocytes implicated in atherosclerosis progres-
sion include Th-2 cells, which produce IL-4, and Th-17 cells, which
produce IL-17 (49–51). The inflammasome-induced cytokines
IL-18 and IL-1β play an important role in the polarization of Th-1
and Th-17 responses (52). Because inhibition of IRE1 suppressed
inflammasome activation (Fig. 3C and Fig. S4 D and E) and IL-1β
production in lipid-challenged macrophages (Fig. 2) as well as le-
sions and tissues (Fig. 5C and Fig. S9 A and B), we next assessed
the impact of IRE1 inhibition on systemic IL-18 levels and Th cell
differentiation in hyperlipidemic mice. ApoE−/− mice (on Western
diet) that were treated with STF-083010 displayed a significant
decrease in plasma IL-18 levels (Fig. 6A) (P < 0.05) and a marked
reduction in the secretion of IFN-γ—but not IL-4 or IL-17—from
splenocytes (P < 0.001) (Fig. 6 B–D and Fig. S9 C–E). We did not
observe changes in the overall T-cell counts in atherosclerotic le-
sions after STF-083010 treatment (Fig. S8E), indicating that de-
creased lymphokine production is intrinsic to intracellular signaling
and does not result from a decline in the infiltrating immune cells
that produce them. In conclusion, the reduced inflammasome ac-
tivity in these mice (as measured by IL-1β and IL-18 levels in Figs.
5C and 6A) after STF-083010 treatment correlates with the sup-
pression of the Th-1 inflammatory response that is known to pro-
mote atherosclerosis development.
Discussion
Studies in mice and humans suggest that chronic ER stress plays an
important role in atherosclerosis progression. Therefore, pharma-
cological manipulation of the UPR—the network of signaling
pathways that respond to ER stress—represents a promising ther-
apeutic approach to manage atherosclerosis (7, 14, 53). The recent
discovery of highly selective UPR modulators provides unique op-
portunities to investigate the contribution of individual UPR
branches to the pathogenesis of this disease. Using small molecules
that target IRE1, we showed that modulating IRE1 signaling
counteracts atherosclerotic plaque formation in mouse models.
First, IRE1 inhibition altered plaque cellular composition
mainly by reducing the numbers of macrophages in the athero-
sclerotic lesions without altering apoptosis. We infer that this
effect is likely to stem from reduction in CCL2, a strong mac-
rophage chemoattractant, consistent with our observations in
macrophages treated with IRE1 inhibitors. Alternatively, IRE1
modulators could impact macrophage clearance from lesions by
phagocytosis of dying cells. We observed no change in the apo-
ptotic cell counts in lesions, arguing against this possibility.
Nevertheless, more detailed future studies are required to dis-
criminate between these two possibilities.
Second, IRE1 inhibitor-treated mice displayed an increased
collagen content in atherosclerotic lesions, which imparts tensile
strength and elasticity to the plaques (54). However, we did not
observe an increase in fibrous cap thickness on IRE1 inhibitor
treatment. Because we observed no differences in the number of
VSMCs in the lesions, the increased collagen deposition may be
related to increased collagen folding and secretion, which is con-
sequential to enhanced ER function coupled to reduced cleavage by
MMPs. In fact, early in our study, we observed that MMP9 is reg-
ulated by IRE1, whereas another study reported RIDD-dependent
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Fig. 4. IRE1 inhibitors reduce plaque area in a mouse model of atherosclerosis. (A) Experimental design in ApoE−/− mice using STF-083010 (10 mg/kg per day).
(B) En face aorta analysis of atherosclerotic plaques in ApoE−/− mice. (Left) Sudan IV staining of atherosclerotic plaques. (Right) Quantification of plaque area
(n = 13–14). (C) Analysis of aortic sinus plaque area in the animals in A and B. (Left and Center) Oil Red O staining of aorta cross-sections. (Right) Quanti-
fication of plaque area (n = 5–6). (D–F) Experimental design and data for analogous experiments in ApoE−/− mice using 4μ8c (10 mg/kg per day; E, n = 7–9; F,
n = 5). Statistics are the same as in Fig. 1. (Scale bar: 350 μm.) *P ≤ 0.05; ***P ≤ 0.001.
E1400 | www.pnas.org/cgi/doi/10.1073/pnas.1621188114 Tufanli et al.
collagen degradation during ER stress (55). Both observations lend
support to our findings and substantiate our hypotheses.
Third, the results from our RNA-seq analyses in macrophages
that were treated with IRE1 inhibitors strongly hinted at IRE1’s
involvement in the production of several proatherogenic cyto-
kines, chemokines, and their receptors, including IL-1β, CCL2,
and chemokine receptor 2. Indeed, IRE1, through XBP1s, reg-
ulates Il-1β and Ccl2 mRNA induction in lipid-stressed macro-
phages. Moreover, oxidative stress can activate NF-κB and
production of CCL2, resulting in the recruitment of monocytes
to a growing plaque (7).
Fourth, cholesterol crystals, saturated fatty acids, and ROS
accumulate in plaque areas and provide activation signals for
activation of the NLRP3 inflammasome and subsequent secretion
of IL-1β and IL-18 (44). These cytokines generate Th-1–type
immune responses that promote plaque progression and unstable
lesions (52). Treatment of macrophages with the IRE1 inhibitors
suppressed lipid-induced mtROS production, activation of the
NLRP3 inflammasome, and subsequent IL-1β secretion. Our re-
sults, therefore, implicate IRE1 activation in the perpetuation of
lipid-induced mitochondrial oxidative stress upstream of NLRP3
inflammasome activation, but our data show that this effect is
independent of TXNIP induction or calcium mobilization (35, 44).
Macrophage mitochondrial oxidative stress plays an important
role in atherogenesis by amplifying inflammation (56). Our results
reveal that IRE1 is crucial for the regulation of mtROS generation
during lipid-induced ER stress; however, future detailed studies
will be needed to uncover how this is achieved by IRE1. In ad-
dition to our findings in cells, we confirmed the inhibitory effect of
IRE1 inhibitors on hypercholesterolemia-induced IL-1β and IL-18
production in vivo in plaques and plasma, respectively. Consistent
with these observations, treatment with IRE1 inhibitors led to a
marked suppression of hyperlipidemia-induced Th-1 immune re-
sponses in these mice. We observed no differences in T-cell
numbers in adventia/lesions between the IRE1 inhibitor treat-
ment and control groups, and previous studies have shown the
IRE1 inhibitor used in this study does not affect Treg cells
(33, 37). Collectively, these findings show that prevention of
inflammasome-associated cytokine production by IRE1 inhib-
itors in vivo has dramatic effects on counteracting atheroscle-
rotic disease progression. Our findings correlating suppression
of IL-1β with atheroprotection are timely in view of a major
ongoing clinical trial on the effect of an anti–IL-1β trial in
coronary artery disease (by Cantos). Although our data show a
clear impact of IRE1 inhibition on macrophage inflammatory
functions, activation of the UPR also occurs in many other
lesion-resident cell types. Thus, our results do not exclude the
possibility that the antiatherogenic effects of IRE1 inhibition
could also involve other lesion-resident cell types that con-
tribute to atherogenesis.
Fifth, the reduction in plaque inflammation and size occurred
independent of a correction of elevated plasma lipid levels in IRE1
inhibitor-treated ApoE−/− mice. This notion contrasts with results
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Fig. 5. IRE1 inhibitors alter plaque composition and inflammation. Immunohistochemical and TUNEL assay analyses of proximal aorta cryosections from
ApoE−/− mice (Fig. 4) treated with an IRE1 inhibitor. In each case, a representative image is shown in Left and Center, and the quantification of the data
appears on in Right. (A) MOMA-2. (Scale bar: 100 μm.) (B) TUNEL assay (apoptotic cells are shown with arrowheads). (Scale bar: 50 μm.) (C) IL-1β. (Scale bar:
100 μm.) Statistics are the same as in Fig. 1. ns, not significant. *P ≤ 0.05; **P ≤ 0.01.














of Xbp1 displayed a profound reduction in plasma cholesterol and
triglyceride levels (57). However, it is important to note that this
apparent disparity may exclusively result from feedback activation
of IRE1 on genetic loss of Xbp1 (57). Notably, additional siRNA-
mediated IRE1 depletion partially reverted the hypolipidemic
phenotype in vivo, hinting at an RIDD-dependent function that
controls lipid metabolism (30). Furthermore, we did not observe
feedback activation of IRE1 or any signs of liver toxicity with the
IRE1 modulators. Because XBP1s promotes the transcriptional
up-regulation of a lipogenic gene program, these findings could be
interpreted to mean that the splicing and RIDD outputs of IRE1
have opposing effects on lipid metabolism (30). Although most of
the direct targets of XBP1 participating in triglyceride and sterol
lipogenic programs were also identified as RIDD substrates in this
study (ref. 30, figure 3), IRE1 (through its RIDD modality) seems
to be able to reduce the steady-state expression of a larger number
of lipogenic genes independent of XBP1, hinting at a complex
lipogenic regulatory program that depends on the interplay be-
tween XBP1 and IRE1 signaling (30, 57). Thus, the reduction in
plaque size that we observed in our study is likely to result from
IRE1 inhibitor-mediated antiinflammatory changes and not to re-
sult from the product of changes in lipid metabolism.
Although we have seen important gains in mitigating athero-
sclerosis by pharmacologically targeting IRE1 in our experimental
models, it is important to note that the other UPR branches, par-
ticularly the PERK-CHOP branch, are also induced as atheroscle-
rosis progresses and seem to be instrumental for macrophage
apoptosis (5, 11). Previous studies focusing on the engagement of
apoptotic pathways initiated by the UPR (such as those mediated
by CHOP and JNK) showed that mice deficient for these apoptotic
effectors are protected from atherosclerosis (5, 11–13). In-
dependent of CHOP or JNK engagement, here, we found that
modulating IRE1 signaling in vivo with small molecule IRE1 in-
hibitors modifies a different branch of UPR signaling that impinges
on metaflammation and alters the course of atherosclerosis. These
results support the notion that it may be possible to uncouple
metabolically induced ER stress from inflammation by calibrating
UPR signaling, thereby improving the clinical outcome of athero-
sclerosis. With the advent of specific inhibitors that can target dif-
ferent UPR branches, exploring the efficacy of combinatorial UPR
calibration in this chronic disease setting becomes a promising
endeavor.
Experimental Procedures
A list of primers used in the study can be found in Dataset S1.
Reagents and Plasmids. IRE1−/− MEFs were provided by Gokhan Hotamişligil,
Harvard School of Public Health, Cambridge, MA. BMDMs were isolated
from C57BL/6 mice. Plasmids encoding XBP1s (21833) and WT IRE1α (13009)
were purchased from Addgene. L-Glutamine, DMEM, PBS, HBSS, penicillin/
streptomycin (P/S), FBS, and Roswell Park Memorial Institute (RPMI)-1640
medium were obtained from Thermo Scientific or HyClone (GE Healthcare
Life Sciences). Trypsin, ampicillin, kanamycin, Bradford assay reagents,
ultrapure LPS, PA (palmitic acid), phosphatase inhibitor mixture, and
STF-083010 were purchased from Sigma-Aldrich; 4μ8c was purchased from
Calbiochem. Primary antibodies used for immunoblotting were purchased
from the following suppliers: anti-IRE1 phospho-S724 antibody (ab48187;
Abcam), IL-1β (ab9722; Abcam), IRE1α rabbit mAb (3294; Cell Signaling),
β-Actin (sc-47778; Santa Cruz Biotechnology), β-actin (sc-9104; Santa Cruz
Biotechnology), Caspase-1 (M20; sc-514; Santa Cruz Biotechnology), and IL-1β
(AF-401-NA; R&D Systems). ECL Prime Western Blot Detection Kit was purchased
from Amersham Pharmacia. ALT assay (MAK052) was from Sigma-Aldrich.
Preparation of PA-BSA Complex. PA was dissolved in absolute ethanol to yield
a stock concentration of 500 mM and stored at −80 °C. Stock PA was diluted
to the working concentration and suspended with 1% fatty acid-free BSA in
RPMI-1640 medium (without serum) by mixing at 50 °C for 30 min.
Preparation of Cholesterol Crystal. The 10-mg/mL cholesterol solution was
prepared in ethanol, heated to 60 °C, brought to room temperature to allow
for crystallization, washed with PBS, and resuspended in RPMI-1640 medium
at 5 mg/mL; 400-μg/mL cholesterol crystals were used for treating the cells
(for 20 hours) as described (58).
Cell Culture and Treatments.
Isolation of BMDMs. Bone marrows were collected from the tibia and femurs of
mice into RPMI-1640 medium containing 1% P/S. After filtering through a cell
strainer (352350; BD Biosciences), the cells were centrifuged at 400 ×g for 5min
and resuspended in RPMI-1640 medium enriched with 15% (vol/vol) L929
conditioned medium and 1% P/S followed by seeding for growth and differ-
entiation into macrophages on Petri dishes for 7 d.
Inflammasome activation. BMDMs were pretreated (1 h) with 150 μM STF-
083010 or the indicated concentrations of 4μ8c followed by stimulation with
ultrapure LPS (200 ng/mL) for 3 hours and then, followed by treatment with
PA-BSA (1,000 μM) for 20 hours. Human PBMCs were purchased from Zenbio
and grown in lymphocyte medium (RPMI-1640, 2 mM L-glutamine, 10% (vol/vol)
FBS, 1% P/S) according to the instructions provided by the manufacturer.
Cells were pretreated with 100 μM 4μ8c before stimulation with ultrapure LPS
(200 ng/mL) for 3 hours. These incubations were followed by treatment with
ethanol-BSA (control) or PA-BSA (500 μM). LPS-primed BMDMs were treated
with various inflammasome inducers, including 5 nM ATP (Sigma-Aldrich),
200 μg/mL Imject Alum (Thermo Scientific), and 1 μg/mL Flagellin (Invivo-
gen) either alone or in combination with 100 μM 4μ8c. Lipofectamine 3000
was used for poly(dA:dT) DNA (5 μg/mL) transfection as described (43).
Induction of mtROS. BMDMs were pretreated (1 h) with 100 μM 4μ8c followed
by sequential stimulation with 200 ng/mL LPS (3 hours) and then, PA-BSA
(1,000 μM) or vehicle (ethanol)-BSA (control) for 20 hours.
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Fig. 6. IRE1 inhibitors suppress hyperlipidemia-induced Th-1 immune re-
sponses and IL-18 cytokine levels. (A) Plasma IL-18 in ApoE−/− mice (Fig. 4)
treated with an IRE1 inhibitor was measured by ELISA (n = 7). (B–D) Flow
cytometry analysis of IFN-γ, IL-4, and IL-17 in splenocytes from ApoE−/− mice
treated with IRE1 inhibitor and activated with PMA/ionomycin (n = 5). Sta-
tistics are the same as in Fig. 1. ns, not significant. *P ≤ 0.05; ***P ≤ 0.001.
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Western Blot Analysis. Cells were lysed in lysis buffer [50 mM Hepes, pH 7.9,
100 mM sodium chloride, 10 mM EDTA, 10 mM sodium fluoride, 4 mM
tetrasodium diphosphate, 1% Triton X-100, 2 mM sodium orthovanadate,
1 mM PMSF (phenylmethylsulfonyl), 1× phosphatase inhibitor mixture
(Sigma-Aldrich), 1× protease inhibitor mixture (Sigma-Aldrich)]. Lysates were
cleared by brief centrifugation followed by the addition of 5× SDS loading
dye. For the detection of cleaved caspase-1 (active p10 form) in the cell
medium, cell culture supernatants were collected, mixed with 5× SDS load-
ing dye, and heated at 95 °C for 5 min before loading on SDS/PAGE gels.
Proteins were subjected to SDS/PAGE separation and transferred onto PVDF
membranes. Blocking and antibody incubation were carried out in TBS (Tris-
buffered saline) with 0.1% (vol/vol) Tween-20 and 5% (wt/vol) dry milk or
BSA and visualized by ECL in a BioRad Imager.
Transfection. IRE1−/− MEFs that reached 60–80% confluency were transfected
with the indicated plasmids (2 μg DNA for every 4.5 × 105 cells) and poly-
ethylenimine (Sigma-Aldrich), and BMDMs were electroporated using a
Neon Electroporator (Invitrogen) according to the protocols provided by
the manufacturer.
RNAi. BMDMs were transfected with 50 nM siRNA against ire1 (SI0099588;
Qiagen), 70 nM siRNA against Xbp1 (SI01473227; Qiagen), or scrambled
siRNAs (1027281; Qiagen); 24 hours after transfection, the cells were treated
with indicated reagents.
RNA Isolation and qRT-PCR. Trisure (Bioline) was used to isolate total RNA from
cells and reverse-transcribed using the RevertAid First Strand cDNA Synthesis
Kit (K1691; Thermo Scientific) according to the manufacturer’s protocols.
cDNAs were amplified using specific primers on a Rotor Gene (Qiagen) real-
time PCR instrument. Roche SYBR Green was used for qRT-PCR. Quantifica-
tions were performed using the ΔΔCt (threshold cycle) method, and gene
expression levels were normalized to Gapdh transcript levels using the fol-
lowing expression: (primer efficiency)−ΔΔCt, where ΔΔCt means ΔCt (target
gene) − ΔCt (reference gene). We analyzed the results from three or more
independent experiments using the Student’s t test.
RNA-Seq Library Preparation and Sequencing. Total RNA was isolated from
control and IRE1-inhibited (with STF-083010) BMDM samples using Trisure
(Bioline). To remove genomic DNA contamination, the RNA samples were
treatedwith 20 U DNase I (New England Biolabs). rRNAwas depleted from 5 μg
total RNA using Ribo-Zero Gold rRNA Removal Kit (Epicentre Biotechnologies)
following the manufacturer’s recommendations. Sequencing libraries for
whole-transcriptome analysis were prepared using the ScriptSeq v2 RNA-Seq
Library Preparation Kit (Epicentre Biotechnologies) following the manufac-
turer’s recommendations. After 3′-terminal tagging, the di-tagged cDNA was
purified using column concentrators (DNA clean-up and concentrators; Zymo
Research). The cDNA libraries were bar-coded to allow sample multiplexing
using ScriptSeqTM Index PCR Primers (Epicentre Biotechnologies). The librar-
ies were amplified by 12 cycles of PCR, and the amplified libraries were
size-selected and purified using 8% TBE (Tris/borate/EDTA) acrylamide
gels. The libraries were quantified using Agilent Technologies 2100 Bio-
analyzer. Up to four RNA-seq libraries were then multiplexed in a single
lane of an Illumina HiSeq2500 Deep-Sequencer Flow Cell (University of
California, San Francisco Center for Advanced Technologies) and sequenced us-
ing 50-bp single-end sequencing chemistry.
RNA Sequencing Data Processing. The 3′ adapter sequences (AGATCGGAA-
GAGCACACGTCTGAAC) were removed from the sequenced libraries using
the FastQ/A clipper found in the FastX Toolkit (hannonlab.cshl.edu/
fastx_toolkit/) after d-multiplexing, and only reads longer than 20 nt were
kept for alignment. The adapter-stripped reads were then aligned with the
Bowtie indices for the mouse genome reference version 10 of the University
of California, Santa Cruz Genome Browser (mm10) using the splice junction
mapper Tophat2 v2.0.9 and the sequence aligner Bowtie 2 V2.2.3.0 with
default parameters. The transcript assembler Cufflinks V2.1.1 was then used
on the list of mapped reads to assemble and quantify transcripts using an
mm10 reference annotation and masking mitochondrial, rRNA, and tRNA
sequences. To estimate the changes in gene expression levels, the number of
sequenced reads that align to a gene of interest was then compared among
biological samples using Cuffdiff (default parameters). Changes in the levels
of expression of normalized Cufflinks-quantified transcripts are expressed as
fragments per kilobase of transcript per million mapped reads (FPKM).
Flow Cytometric Analysis of Intracellular Cytokine Staining. Fresh splenocytes
were prepared from mice spleen, and erythrocytes were removed using RBC
(red blood cell) lysis buffer as described earlier (43). Cells were stimulated for
4 hours with phorbol-myristate-acetate (PMA; 50 ng/mL; Abcam) and ionomycin
(1 μg/mL; Abcam) in the presence of Golgi stop (BD Biosciences). Live cells were
discriminated from dead ones by using Zombie Green (Bio Legend). Cell surfaces
were stained with PerCP-Cy5.5–conjugated anti-CD4 antibody (BD Biosciences)
followed by incubation in Cytofix/Cytoperm Solution (BD Biosciences) at room
temperature for 15 min. Then, intracellular cytokines were stained with
allophycocyanin (APC)-conjugated IFN-γ, phycoerythrin (PE)-conjugated IL-17A,
and PE-conjugated IL-4 antibodies (all from BD Biosciences). Data were ana-
lyzed on BD Accuri C6 software.
Measurement of Secreted IL-1β and IL-18 and CCL2 Cytokines. An IL-1β Elisa Kit
(Abcam) was used for detecting IL-1β; a Mouse IL-18 ELISA Kit (Medical &
Biological Laboratories) and a Mouse CCL2 Elisa Kit (Abcam) were used for
detecting the cytokines in mouse plasma or conditioned medium, re-
spectively, as indicated according to the manufacturer’s instructions.
Plasma Measurements. FPLC was used for analyzing the size distribution of
lipoproteins. All measurements were carried out at the Mouse Metabolic
Phenotyping Center at the University of Cincinnati. For the resolution of major
lipoprotein classes from plasma; the columns were equilibrated in 50 mM PBS.
Using amicrotiter plate enzyme-based assay, themajor lipoprotein classes were
measured in cholesterol or triglyceride assays from collected fractions.
Staining of Cryosections. Cryosections (7-μm thick) were cut from the aortic
root of the frozen heart tissue with a cryostat (Leica CM1850) and stained with
Oil Red O, anti–MOMA-2 (monocyte/macrophage marker) (ab33451; Abcam),
anti–CD3-Alexa488 (1:400; Biolegend), TUNEL Kit (11684795910; Roche), anti–
α-SMA (ab5694; Abcam), and IL-1β antibody (ab9722; Abcam). Immunofluo-
rescent staining was mounted with an antifade reagent including DAPI
(GR211467-2; Abcam). Representative images were taken with a Zeiss Fluo-
rescent Microscope. Collagen content of the lesions and fibrous cap thickness
were determined in Masson’s Trichrome-stained lesions (as per the manufac-
turer’s protocol; Bio-Optica). Fibrous cap thickness was calculated according to
the published protocol (59). Heart tissue sections were stained with Oil Red O
stain for plaque area quantifications and H&E for necrotic core quantification
in accord with previously published protocols (43). All quantifications were
performed using ImageJ (NIH). Percentage of average cross-sectional stained
area per leaflet was calculated from all three valves.
Atherosclerotic Lesion Analysis. Aortas were pinned on a black wax surface,
and atherosclerotic lesions were analyzed in the aortic arch and descending
aorta by Sudan IV staining as described earlier (43). Areas were quantified
using ImageJ and expressed as the percentages of the total aorta area.
Quantification of mtROS.mtROS production was measured with MitoSOX Red
Mitochondrial Superoxide Indicator (M36008; Life Technologies) according to
the protocol provided by the company. Representative images were acquired
with a confocal microscope (LSM 510; Zeiss) and analyzed with ImageJ.
Mitochondrial Calcium Measurement. RHOD-2 AM (cell-permeable fluorescent
calcium indicator) (Thermo Scientific) was used for mitochondria-specific
calcium measurement according to previously published protocols (60).
Mice and Treatments. ApoE−/− mice in a C57BL/6 background (Charles River
WIGA GmbH) were used in atherosclerosis experiments. Starting from 8
weeks of age, male mice were fed a Western diet (TD88137 mod. containing
21% fat and 0.2% cholesterol; Ssniff) for 6 weeks. Then, the mice were in-
jected with STF-083010 (10 mg/kg) or DMSO, both given in 16% (vol/vol)
Cremophor EL (Sigma-Aldrich) saline solution via i.p. injections as described
previously, for 6 more weeks while mice were continued on the Western diet
(21). The other ApoE−/− mice that were used in atherosclerosis experiments
were fed a Western diet for 8 weeks. Then, they were injected with 4μ8c
(10 mg/kg) or DMSO, both given in 16% (vol/vol) Cremophor EL saline so-
lution via i.p. injections as described previously (33), for 4 more weeks while
mice were continued on Western diet. Weights were measured every other
day, whereas blood glucose concentrations were measured before and after
treatments. At the end of the experiment, mice were anesthetized, and
blood was collected by cardiac puncture. Bone marrow, spleen, and liver
tissues were collected, frozen immediately into liquid nitrogen, and stored
at −80 °C. Perfusion was performedwith ice-cold PBS and heparin (1,000 U/mL)
followed by 10% formalin solution (Sigma). After fixation, the aorta was














dissected intact, immersed immediately in 10% formalin, and stored at 4 °C
until analysis. The heart was removed at the proximal aorta, placed into a
tissue mold, covered with OCT (optimal cutting temperature compound)
(Tissue-Tek), frozen in cold isobutene solution, and stored at −80 °C. All animal
experiments were performed according to protocols approved by the Experi-
mental Animal Care Committee at Bilkent University.
Statistical Analysis. Values are expressed as mean ± SEM. No samples were
treated as outliers and left out of analysis. Statistical significance was evaluated
using the Student’s t test or the Mann–Whitney test (for in vivo analysis as in-
dicated in the figures). P < 0.05 was considered as significant.
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